NCT05011669已完成4 期
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia: A Multi-Center, Prospective, Open-Label Study for 6 Weeks
Sumitomo Pharma (Suzhou) Co., Ltd.1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2021年8月16日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Percentage of discontinuation due to adverse events
研究概览
简要总结
To evaluate the safety and efficacy of Lurasidone initiated with 40mg and 80mg in treatment with acute phase patients with schizophrenia
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects meet ICD10 criteria for a primary diagnosis of schizophrenia;
- •Subjects have a score ≥ 4 on the CGI-S at Screening and Baseline;
- •Subjects have a PANSS total score ≥ 70 and ≤ 120 at Screening and Baseline, with a score 4 (moderate) or higher in 2 or more items on the following PANSS items: delusions, conceptual disorganization, hallucinations, unusual thought content and suspiciousness;
- •Subjects with acute (including recurrence /relapse and first episode) phase patients with schizophrenia;
- •Ability to understand the contents of interview and provide written informed consent (If subject is unable to sign, subject's legal guardian or impartial witness shall sign the informed consent).
排除标准
- •Subjects with severe or unstable physical diseases (including but not limited to severe or unstable cardiovascular diseases, cerebrovascular diseases, liver and kidney diseases) determined by the investigators;
- •Subjects had a history of stomach or intestinal surgery or any other condition that could interfere with absorption, distribution, metabolism, or excretion of medications;
- •Based on the judgement of investigators, subject has a history of refractory psychosis and/or subject has been treated with clozapine (for any reason) within 4 months of baseline;
- •Subjects has used long-term antipsychotic drugs, e.g. Haloperidol decanoate injection, Fluphenazine decanoate injection, Risperidone microspheres injection, Paliperidone palmitate injection, Paliperidone palmitate injection (3M), in the following time prior to the enrolment;
- •Subjects is at risk of suicide or self-mutilation behaviours or the act of endangering others, or other corresponding characteristic behaviour, or a history of suicide;
- •Female subjects were pregnant (positive pregnancy test at screening) or breast-feeding or planning pregnancy for the duration of the study, or the partners of male subjects were planning pregnancy for the duration of the study;
- •Need to use of disallowed concomitant therapy which is specified in the protocol;
- •History of severe allergy or hypersensitivity;
- •Currently has severe liver function impairment, or serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥3 times the upper limit of normal value;
- •Creatinine clearance rate < 50mL/min Creatinine clearance rate*100%= Male: (140 - Age) x Weight(kg)/Serum creatinine (mg/dL) x 72 Female: 0.85*(140 - Age) x Weight(kg)/Serum creatinine (mg/dL) x 72
- •A history of malignant tumors (including benign pituitary tumors);
- •Any chronic organic disease of the central nervous system (excluding schizophrenia), such as CNS related tumors and inflammation, active seizures, vascular disease, Parkinson's disease, Alzheimer's disease, or other forms of dementia, myasthenia gravis, and other degenerative diseases. A history of mental retardation or persistent neurological symptoms caused by severe head injury;
- •Subjects received electroconvulsive therapy (ECT) within 90 days prior to screening, or were expected to require ECT during the study;
- •A history of neuroleptic malignant syndrome;
- •Severe tardive dyskinesia, severe dystonia, or any other severe dyskinesia;
- •Angioedema occurred after previous administration of lurasidone;
- •The subject is participating in or has participated in other clinical trials, including the use of commercially available drugs or medical devices, within 30 days prior to the signing of the informed consent;
- •Patients who had previously participated in a clinical study of lurasidone;
- •Any other conditions judged by the investigators that not suitable to participate in this study.
研究组 & 干预措施
Latuda® 40mg/d
Experimental
干预措施: Lurasidone (Drug)
Latuda® 80mg/d
Experimental
干预措施: Lurasidone (Drug)
结局指标
主要结局
Percentage of discontinuation due to adverse events
时间窗: during the 6 weeks of treatment
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
High Dose Lurasidone for Patients With Treatment Resistant SchizophreniaSchizophreniaNCT01569659Northwestern University101
尚未招募
不适用
Efficacy And Safety Of Lurasidone Versus Lamotrigine As An Adjunct Therapy In Bipolar-II DepressioCTRI/2022/01/039683Government medical college patiala
已完成
1 期
Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human SubjectsSchizophreniaNCT02174523Sumitomo Pharma (Suzhou) Co., Ltd.14
终止
4 期
The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From OlanzapineSchizophreniaNCT05213143Sumitomo Pharma (Suzhou) Co., Ltd.13
已完成
3 期
A Phase III study of SM-13496 in patients with schizophreniaSchizophreniaJPRN-jRCT2080223187Sunovion Pharmaceuticals Inc.,483